Table 5.

Summary of studies describing the impact of BM in RCC.

Study	Patients	Agent	Response Rate	Median PFS (months)	Median OS (months)
Negrier et al (2002)[8]	782	Cytokine- based	NR	NR	8.8 vs. 15.7a
Choueiri et al (2007)[19]	120	Anti-VEGF therapy	NR	10.7 vs. 16.5	NR
Donskov et al (2006)[5]	120	Cytokine- based	NR	NR	12 vs. 19a
Riechelmann et al (2008)[20]	58	Sorafenib	NR	4.7 vs. 11.2a	NR
Beuselinck et al (2011)[10]	223	Sunitinib	35% vs. 55%a	8.2 vs. 19.1a	19.5 vs. 38.5a
Patil et al (2011)[21]	375	Sunitinib	NR	NR	BM independent risk factor for worse OS
Motzer et al (2010)[11]	416	Everolimus	NR	BM independent risk factor for worse PFS	BM independent risk factor for worse OS

^aSignifies statistical significance.

Not recorded (NR).